76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ventyx Biosciences Inc
Closed
2.45 8.89
Overview
Share price change
24h
Min
2.22
Max
2.46
Income | 1.9M -27M |
|---|---|
EPS | -0.39 |
Employees | 81 |
EBITDA | 2.4M -30M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +779.4% upside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | 42M 145M |
|---|---|
Previous open | -6.44 |
Previous close | 2.45 |
Ventyx Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ventyx Biosciences Inc Forecast
Price Target
By TipRanks
779.4% upside
12 Months Forecast
Average 17.5 USD 779.4%
High 21 USD
Low 14 USD
Based on 5 Wall Street analysts offering 12 month price targets forVentyx Biosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
